Literature DB >> 8878567

Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Y Q Zhu1, K M Remington, T W North.   

Abstract

We selected mutants of feline immunodeficiency virus (FIV) that are resistant to 2',3'-dideoxy-2',3'-didehydrothymidine (d4T). Two mutants were selected in cultured cells with a stepwise increase in d4T concentration, resulting in mutants able to replicate in 100 microM d4T. These mutants were three- to sixfold more resistant to d4T than wild-type FIV. They were also cross-resistant to 3'-azido-3'-deoxythymidine (AZT), 3'-fluoro-2',3'-dideoxythymidine, 2',3'-dideoxycytidine, 2',3'-dideoxyinosine, and 9-(2-phosphonylmethoxyethyl)adenine, and they were highly resistant to phosphonoformic acid (PFA). Plaque-purified mutants were isolated from each of the mutant populations. The mutant phenotype was stable, because both of the plaque-purified mutants remained d4T resistant even after three passages in the absence of d4T. One of the plaque-purified mutants, designated D4R-3c, was further characterized. Compared with wild-type reverse transcriptase (RT), RT purified from D4R-3c was 3-fold resistant to inhibition by the 5'-triphosphate of d4T, 10-fold resistant to inhibition by the 5'-triphosphate of AZT, and 6-fold resistant to PFA. D4R-3c had a single point mutation in the RT-encoding region of the pol gene at position 2474, resulting in a Val to Ile mutation at codon 47 of the FIV RT. The role of this mutation in d4T resistance was confirmed by site-directed mutagenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878567      PMCID: PMC163459     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

Review 1.  HIV inhibitors targeted at the reverse transcriptase.

Authors:  E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

2.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

5.  Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2'-deoxyadenosine-5'-triphosphate.

Authors:  R C Cronn; K M Remington; B D Preston; T W North
Journal:  Biochem Pharmacol       Date:  1992-10-06       Impact factor: 5.858

6.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

7.  AIDS-associated encephalopathy with experimental feline immunodeficiency virus infection.

Authors:  M Podell; M Oglesbee; L Mathes; S Krakowka; R Olmstead; L Lafrado
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-07

8.  Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Q Gao; Z Gu; J Hiscott; G Dionne; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.

Authors:  J E Fitzgibbon; R M Howell; C A Haberzettl; S J Sperber; D J Gocke; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 10.  Clinical correlates and molecular basis of HIV drug resistance.

Authors:  M A Wainberg; Z Gu; Q Gao; E Arts; R Geleziunas; S Bour; R Beaulieu; C Tsoukas; J Singer; J Montaner
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993
View more
  5 in total

1.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.

Authors:  R A Smith; K M Remington; B D Preston; R F Schinazi; T W North
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.

Authors:  Hiroaki Togami; Kazuya Shimura; Munehiro Okamoto; Rokusuke Yoshikawa; Takayuki Miyazawa; Masao Matsuoka
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

4.  Phylogenetic and genetic analysis of feline immunodeficiency virus gag, pol, and env genes from domestic cats undergoing nucleoside reverse transcriptase inhibitor treatment or treatment-naïve cats in Rio de Janeiro, Brazil.

Authors:  Angelica N Martins; Sheila O Medeiros; Jose P Simonetti; Hermann G Schatzmayr; Amílcar Tanuri; Rodrigo M Brindeiro
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

Review 5.  Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.

Authors:  Katrin Hartmann; Anita Wooding; Michèle Bergmann
Journal:  Vet Sci       Date:  2015-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.